샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793799

세계의 로사이돌프만병 시장

Rosai-Dorfman Disease
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 372 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

로사이돌프만병 세계 시장은 2030년까지 8억 4,700만 달러에 달할 전망

2024년에 6억 2,780만 달러로 추정되는 로사이돌프만병 세계 시장은 2030년에는 8억 4,700만 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 5.1%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 클래식 로사이돌프만병은 CAGR 4.0%를 기록하며 분석 기간 종료시에는 4억 7,760만 달러에 달할 것으로 예측됩니다. 결절외형 로사이돌프만병 부문 성장률은 분석 기간 동안 CAGR 6.8%로 추정됩니다.

미국 시장은 1억 7,100만 달러, 중국은 CAGR 7.9%로 성장 예측

미국의 로사이돌프만병 시장은 2024년에 1억 7,100만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 1억 6,660만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.9%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.6%와 5.0%로 예측됩니다. 유럽에서는 독일이 CAGR 3.3%로 성장할 것으로 예측됩니다.

세계의 로사이돌프만병 시장 - 주요 동향과 촉진요인 정리

희귀질환의 해독: 향상된 진단과 표적치료가 로자이 도르프만 치료의 전망을 재구성하는 방법

로사이돌프만병이란 무엇이며, 왜 진단과 치료가 어려운가?

로사이돌프만병(RDD) 또는 거대 림프절 부종을 동반한 부비동 조직구증은 림프절과 림프절 외 조직에 조직구가 과다하게 생성되고 축적되는 희귀한 비 랑게르한스 세포 조직구증입니다. 대부분 무통성 경부 림프절 부종을 보이지만 피부, 호흡기, 중추신경계 및 기타 장기에 침범할 수 있어 진단이 모호할 수 있습니다. 이 질환은 림프종, 전신성 자가면역질환 등의 악성종양을 모방할 수 있어 조기 정확한 진단이 어려운 질환입니다.

RDD의 발병 기전은 면역 조절 이상이나 감염성 유발 요인이 관여할 가능성이 의심되지만, 아직 충분히 밝혀지지 않았습니다. 느린 림프절 종대부터 침습적인 다장기 병변까지 병태가 다양하기 때문에 치료 전략도 복잡합니다. 전통적으로 이 질환은 자연관해의 가능성이 있기 때문에 보존적으로 관리되어 왔습니다. 그러나 중요한 장기에 병변이 있거나 외관을 해칠 정도로 진행이 된 경우에는 코르티코스테로이드, 면역억제제, 수술적 치료가 필요합니다. KRAS 및 NRAS와 같은 분자 돌연변이를 가진 환자에서 MEK 억제제를 포함한 표적 치료의 유용성이 새로운 증거에 의해 입증되어 보다 맞춤화된 치료의 미래를 예고하고 있습니다.

진단 혁신은 RDD의 임상 상황을 어떻게 변화시키고 있는가?

병리조직학적 분석은 엠페리포레시스, S100+ 조직구 등의 특징적인 특징을 가진 로자이-도르프만 병을 진단하는 데 있어 여전히 표준으로 사용되고 있습니다. 그러나 최근 분자진단학 및 영상 진단의 발전으로 조기발견, 아분류, 모니터링이 개선되고 있습니다. 전체 엑솜 염기서열 분석(WES)과 차세대 염기서열 분석(NGS)을 통해 일부 RDD 환자에서 MAPK/ERK 경로의 재발성 돌연변이가 발견되어 분자 병인 및 잠재적 치료 반응성에 기반한 계층화가 가능해졌습니다.

영상 진단은 질병의 정도와 치료 효과를 평가하는 데 있어 매우 중요한 역할을 합니다. 양전자방사선단층촬영(PET-CT)은 활동성 병변의 식별, 생검의 가이드, 잔존 병변의 모니터링에 점점 더 많이 사용되고 있습니다. 다른 조직구 질환이나 육아종성 질환과의 감별이 중요한 중추신경계 병변의 경우 MRI가 바람직합니다. 또한, 질병 활동과 치료 효과를 추적하기 위해 순환 바이오마커와 사이토카인 프로파일링이 조사되고 있습니다.

이러한 진단의 발전은 조기 개입을 지원하고, 불필요한 외과적 절제술을 피하고, 분자 위험 프로파일에 기반한 치료의 에스컬레이션을 유도함으로써 임상 관리를 재구성하고 있습니다. 진단의 표준화는 이 질환의 희귀성과 임상의의 숙련도 및 진단에 대한 접근성에 지리적 편차가 있다는 점을 고려할 때 특히 중요합니다.

RDD의 영향을 가장 많이 받는 환자 그룹과 헬스케어 시장은?

RDD는 전 세계적으로 분포하고 있지만, 소아, 청소년, 청년, 젊은 성인에 많으며, 다소 남성 우위입니다. 특히, 고급 영상 진단이나 조직학적 전문 지식에 대한 접근이 제한되어 있는 저자원 환경에서는 거의 보고된 바가 없습니다. 많은 사례는 림프절 전이에 국한되어 개입 없이 완치되지만, 상당수(40%)가 림프절 외 침범을 보여 적극적인 관리가 필요합니다.

RDD 진단 및 치료제 시장은 북미, 유럽, 동아시아의 3차 의료센터, 대학병원, 혈액종양 전문 클리닉에서 두드러집니다. 미국과 일본은 임상 연구에 큰 관심을 보이고 있으며, 학술 등록과 여러 기관의 코호트를 통해 이 질환의 임상 스펙트럼과 치료 결과를 정의하는 데 도움을 주고 있습니다. 희귀질환 전문 제약사들도 파이프라인을 확장하고 있으며, 특히 돌연변이 양성 사례에서 RDD 치료에 재사용할 수 있는 임상시험용 약물을 포함하고 있습니다.

환자 지원 단체, 희귀질환 재단, 정부 지원 연구 이니셔티브는 질병 인식, 진단의 공정성, 실험적 치료에 대한 접근성을 개선하는 데 중요한 역할을 하고 있습니다. 이는 진단이 늦어질수록 결과가 더 나빠지는 경우가 많은 의료 서비스가 부족한 지역과 세계 각지에서 특히 중요합니다.

로사이돌프만병 시장의 원동력은?

로사이돌프만병 시장의 성장은 여러 요인, 특히 분자진단의 발전, 의사들의 인식 개선, 표적화된 맞춤형 치료 프로토콜로의 전환 등 여러 가지 요인에 의해 주도되고 있습니다. 일부 RDD 환자에서 실용화 가능한 돌연변이가 발견되면서 MEK 억제제, 면역관문억제제, 대식세포 활성화를 조절하는 생물학적 제제를 포함한 임상시험의 문이 열렸습니다. 이는 RDD 시장을 경험적 치료를 대체하는 정밀의료가 희귀질환 치료의 광범위한 트렌드와 일치합니다.

출판 활동의 활성화, 세계 RDD 등록의 확립, 조직구 질환에 대한 다학제적 종양위원회의 채택으로 진단율과 치료 경로가 개선되고 있습니다. 신흥국의 의료 시스템은 희귀질환 치료제 개발에 인센티브를 부여하는 유리한 규제 프레임워크에 힘입어 희귀질환 치료제에 더 많은 자원을 할당하고 있습니다. 또한, 조직구증 분류 시스템 및 진단 알고리즘에 RDD가 포함됨으로써 일반 개업의와 전문의의 조기 검진 및 인식이 촉진되고 있습니다.

마지막으로, 디지털 병리학, AI를 활용한 생검 해석, 공동 연구 네트워크의 융합은 진단의 편차를 줄이고 치료 혁신을 가속화합니다. RDD가 수수께끼 같은 희귀질환에서 유전체적으로 특성화되고 임상적으로 계층화된 질환으로 전환됨에 따라, 시장은 전 세계 주요 의료 시스템에서 의약품 개발, 임상시험 및 정밀 진단을 위한 기회를 확대할 것입니다.

부문

유형(클래식 로사이돌프만병, 결절외형 로사이돌프만병), 투여 경로(경구 투여, 비경구 투여, 기타 투여 경로), 최종사용자(병원·진료소 최종사용자, 외래 수술 센터 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Amgen
  • Amicus Therapeutics
  • AstraZeneca
  • Bayer
  • BMS(Bristol-Myers Squibb)
  • GSK(GlaxoSmithKline)
  • Janssen(Johnson & Johnson)
  • Kura Oncology
  • Merck & Co.
  • Novartis
  • Pfizer
  • Protalix BioTherapeutics
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Takeda
  • Ultragenyx Pharmaceutical
  • Vertex Pharmaceuticals
  • Blueprint Medicines
  • Incyte

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.26

Global Rosai-Dorfman Disease Market to Reach US$847.0 Million by 2030

The global market for Rosai-Dorfman Disease estimated at US$627.8 Million in the year 2024, is expected to reach US$847.0 Million by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Classic Rosai-Dorfman Disease, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$477.6 Million by the end of the analysis period. Growth in the Extranodal Rosai-Dorfman Disease segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$171.0 Million While China is Forecast to Grow at 7.9% CAGR

The Rosai-Dorfman Disease market in the U.S. is estimated at US$171.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$166.6 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Rosai-Dorfman Disease Market - Key Trends & Drivers Summarized

Decoding a Rare Disease: How Better Diagnostics and Targeted Therapies Are Reshaping Rosai-Dorfman Treatment Landscape

What Is Rosai-Dorfman Disease and Why Is It Challenging to Diagnose and Treat?

Rosai-Dorfman Disease (RDD), or sinus histiocytosis with massive lymphadenopathy, is a rare non-Langerhans cell histiocytosis characterized by overproduction and accumulation of histiocytes in lymph nodes and extranodal tissues. It often presents with painless cervical lymphadenopathy but may involve the skin, respiratory tract, central nervous system, and other organs, leading to significant diagnostic ambiguity. The disease can mimic malignancies such as lymphoma or systemic autoimmune disorders, making early and accurate diagnosis difficult.

RDD’s pathogenesis remains poorly understood, though it is suspected to involve immune dysregulation or infectious triggers. The heterogeneity in presentation-ranging from indolent lymph node enlargement to aggressive, multi-organ involvement-complicates treatment strategies. Traditionally, the disease has been managed conservatively due to its potential for spontaneous remission. However, in cases of vital organ involvement or disfiguring progression, corticosteroids, immunosuppressants, or surgical intervention may be warranted. Emerging evidence has shown the utility of targeted therapies, including MEK inhibitors, in patients with molecular mutations such as KRAS or NRAS, pointing toward a more personalized treatment future.

How Is Diagnostic Innovation Transforming the Clinical Landscape for RDD?

Histopathological analysis remains the gold standard for diagnosing Rosai-Dorfman Disease, with hallmark features such as emperipolesis and S100+ histiocytes. However, recent advances in molecular diagnostics and imaging modalities are improving early detection, subclassification, and monitoring. Whole exome sequencing (WES) and next-generation sequencing (NGS) have uncovered recurrent mutations in the MAPK/ERK pathway in a subset of RDD patients, allowing stratification based on molecular etiology and potential therapy responsiveness.

Imaging plays a pivotal role in evaluating disease extent and therapeutic response. Positron emission tomography-computed tomography (PET-CT) is increasingly used to identify active lesions, guide biopsies, and monitor residual disease. MRI is preferred in cases of central nervous system involvement, where differentiation from other histiocytic or granulomatous diseases is critical. Additionally, circulating biomarkers and cytokine profiling are under investigation for tracking disease activity and treatment efficacy-tools that could help move toward less invasive longitudinal care models.

These diagnostic advancements are reshaping clinical management by supporting earlier intervention, avoiding unnecessary surgical excisions, and guiding treatment escalation based on molecular risk profiles. Diagnostic standardization is particularly important given the disease’s rarity and geographical variability in clinician familiarity and diagnostic access.

Which Patient Groups and Healthcare Markets Are Most Affected by RDD?

RDD has a global distribution but is more commonly diagnosed in children, adolescents, and young adults, with a slight male predominance. It remains largely underreported, especially in low-resource settings where access to advanced imaging and histological expertise is limited. While many cases are limited to lymph nodes and resolve without intervention, a significant proportion-up to 40%-show extranodal involvement requiring aggressive management.

The market for RDD diagnostics and therapeutics is more pronounced in tertiary care centers, academic hospitals, and specialty hematology-oncology clinics in North America, Europe, and East Asia. The U.S. and Japan have shown strong clinical research interest, with academic registries and multi-institutional cohorts helping to define the disease’s clinical spectrum and treatment outcomes. Pharmaceutical companies focusing on rare diseases are also expanding their pipelines to include investigational drugs that could potentially be repurposed for RDD treatment, particularly in mutation-positive cases.

Patient advocacy groups, rare disease foundations, and government-sponsored research initiatives are playing a crucial role in improving disease awareness, diagnostic equity, and access to experimental therapies. This is particularly important for underserved communities and global regions where delayed diagnosis often results in poorer outcomes.

What Is Driving the Momentum in the Rosai-Dorfman Disease Market?

The growth in the Rosai-Dorfman Disease market is driven by several factors, notably advances in molecular diagnostics, increased physician awareness, and a shift toward targeted and individualized treatment protocols. The discovery of actionable mutations in a subset of RDD patients has opened the door for clinical trials involving MEK inhibitors, immune checkpoint blockers, and biologics that modulate macrophage activation. This aligns the RDD market with broader trends in rare disease therapeutics where precision medicine is replacing empiric treatment.

Increased publication activity, establishment of global RDD registries, and the adoption of multidisciplinary tumor boards for histiocytic disorders are improving diagnostic rates and care pathways. Health systems in developed economies are allocating more resources for orphan diseases, aided by favorable regulatory frameworks that incentivize orphan drug development. The inclusion of RDD in histiocytosis classification systems and diagnostic algorithms is also encouraging earlier screening and recognition among general practitioners and specialists alike.

Lastly, the convergence of digital pathology, AI-enabled biopsy interpretation, and collaborative research networks is set to reduce diagnostic variability and accelerate therapeutic innovation. As RDD shifts from an enigmatic and rare disorder to a genomically characterized and clinically stratified disease, the market will see expanded opportunities for pharmaceutical development, clinical trials, and precision diagnostics across key healthcare systems worldwide.

SCOPE OF STUDY:

The report analyzes the Rosai-Dorfman Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Classic Rosai-Dorfman Disease, Extranodal Rosai-Dorfman Disease); Administration Route (Oral Administration, Parenteral Administration, Other Administration Routes); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Amgen
  • Amicus Therapeutics
  • AstraZeneca
  • Bayer
  • BMS (Bristol-Myers Squibb)
  • GSK (GlaxoSmithKline)
  • Janssen (Johnson & Johnson)
  • Kura Oncology
  • Merck & Co.
  • Novartis
  • Pfizer
  • Protalix BioTherapeutics
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Takeda
  • Ultragenyx Pharmaceutical
  • Vertex Pharmaceuticals
  • Blueprint Medicines
  • Incyte

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Rosai-Dorfman Disease - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnostic Awareness Among Clinicians Throws the Spotlight on Rare Histiocytic Disorders
    • Expansion of Immunohistochemistry and Genetic Profiling Drives Precision in Disease Classification
    • Growth in Rare Disease Registries and Patient Advocacy Strengthens Business Case for Targeted Therapies
    • Increased Availability of Advanced Imaging Tools Propels Early Diagnosis and Monitoring
    • Emerging Research on Immune Dysregulation in Histiocytosis Expands Treatment Pathways
    • Collaborations Between Academic Hospitals and Biotech Firms Accelerate Clinical Understanding
    • Wider Access to Molecular Diagnostic Panels Enhances Disease Subtyping and Case Differentiation
    • Inclusion in Rare Disease Policy Frameworks Generates Reimbursement and Funding Opportunities
    • Off-Label Use of Immunosuppressants and Targeted Therapies Spurs Clinical Trials
    • Growing Emphasis on Non-Langerhans Cell Histiocytosis Drives Demand for Novel Drug Candidates
    • Increased Recognition in Pediatric and Young Adult Populations Expands Diagnostic Vigilance
    • Integration of Electronic Health Records in Rare Disease Tracking Enhances Epidemiological Data
    • Patient-Centric Research Initiatives Propel Compassionate Access to Experimental Therapies
    • Cross-Disciplinary Collaboration in Rheumatology, Oncology, and Pathology Enhances Multimodal Care
    • Genetic Sequencing Studies Strengthen Understanding of Etiopathogenesis and Biomarkers
    • Rising Demand for Case-Based Learning Modules Drives Education in Rare Disease Medicine
    • Market Entry of Specialty Pharma Firms Into Orphan Disease Segments Expands Treatment Pipeline
    • Surge in AI-Based Differential Diagnosis Tools Supports Identification of Atypical Presentations
    • Regulatory Incentives for Orphan Drug Development Propel Innovation in Treatment Strategies
    • Growth in Global Medical Conference Discourse Enhances Awareness and Clinical Reporting
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rosai-Dorfman Disease Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Classic Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Classic Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Classic Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Extranodal Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Extranodal Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Extranodal Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Rosai-Dorfman Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Rosai-Dorfman Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: India 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Rosai-Dorfman Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Rosai-Dorfman Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제